Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 80190 refers to a laboratory test specifically designed to measure the levels of procainamide in the blood. Procainamide is a medication classified as a cardiac antidysrhythmic agent, which means it is used to manage and treat irregular heartbeats, particularly ventricular tachycardia. This drug works by blocking abnormal electrical impulses in the heart, thereby helping to restore a normal rhythm. The test may also include the measurement of procainamide metabolites, notably n-acetyl procainamide, which can provide additional insights into the drug's efficacy and safety in the patient’s system. Regular monitoring of procainamide levels is crucial, as it helps healthcare providers ensure that the drug concentration remains within a therapeutic range, minimizing the risk of toxicity and adverse effects. It is important to note that procainamide can lead to the formation of antinuclear antibodies, which may present symptoms similar to systemic lupus erythematosus, a condition that can affect various systems in the body. The blood sample required for this test is obtained through a venipuncture, a procedure that is separately reportable. The analysis of the blood serum is conducted using a technique known as fluorescence polarization immunoassay, which is a sensitive method for detecting and quantifying drug levels in the bloodstream.
© Copyright 2026 Coding Ahead. All rights reserved.
The procainamide blood test (CPT® Code 80190) is indicated for the following conditions:
The procedure for obtaining a procainamide blood test involves several key steps:
After the blood sample has been collected, there are generally no specific post-procedure care requirements for the patient. However, patients may be advised to apply pressure to the venipuncture site to minimize bruising and bleeding. Results from the procainamide test are typically available within a few days, and healthcare providers will review the findings to determine if any adjustments to the patient's medication regimen are necessary based on the procainamide levels measured. It is important for patients to follow up with their healthcare provider to discuss the results and any potential implications for their treatment plan.
| Short Descr | ASSAY OF PROCAINAMIDE | Medium Descr | DRUG SCREEN QUANTITATIVE PROCAINAMIDE | Long Descr | Procainamide; | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Conditionally packaged laboratory tests | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 2 | CCS Clinical Classification | 235 - Other Laboratory |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2013-01-01 | Changed | Medium description changed per AMA 2013 corrections document dated January 25, 2013. |
| 2010-01-01 | Changed | Code description changed. |
| 1993-01-01 | Added | First appearance in code book in 1993. |
Get instant expert-level medical coding assistance.